Taysha Gene Therapies (TSHA) Stock Price, News & Analysis

Company Overview

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company dedicated to developing AAV vector-based gene therapies for rare central nervous system (CNS) diseases. The company’s proprietary platform harnesses tissue-specific promoters and a streamlined development process to address a range of inherited neurological disorders. Taysha’s lead programs are focused on monogenic diseases with high unmet medical need, and its approach aims to deliver durable, one-time treatments that can modify disease progression.

The company’s pipeline includes TSHA-102 for Rett syndrome, TSHA-104 for GM1 gangliosidosis, TSHA-105 for giant axonal neuropathy and TSHA-118 for frontotemporal dementia (FTD) associated with progranulin deficiency. Each candidate employs an adeno-associated virus serotype optimized for CNS delivery and a promoter designed to drive expression in relevant neuronal or glial cell populations. Taysha has reported encouraging preclinical and early clinical data across several programs, demonstrating target engagement and favorable safety profiles in initial cohorts.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies was established by a team of gene therapy veterans with backgrounds at leading academic institutions and biotechnology firms. The company has entered strategic collaborations with academic centers and contract development and manufacturing organizations to accelerate vector production and clinical supply. Taysha’s R&D operations leverage both in-house capabilities and external partnerships to support IND filings and ongoing trials in North America and Europe.

Under the leadership of Chief Executive Officer Mona Sinha, a seasoned executive with extensive experience in translational research and drug development, Taysha continues to expand its footprint in the rare disease community. The management team includes experts in regulatory affairs, clinical operations and vector biology. Taysha is committed to engaging patient advocacy groups and shaping disease awareness, aiming to bring transformative gene therapies to underserved patient populations worldwide.

Key Stats

• Today's Range: $2.59 to $2.73
• 50-Day Range: $1.91 to $2.93
• 52-Week Range: $1.05 to $3.31
• Volume: 3.29 million shs
• Average Volume: 2.94 million shs
• Market Capitalization: $566.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.17
• Consensus Rating: Buy

Taysha Gene Therapies Stock Analysis - MarketRank™

Taysha Gene Therapies scored higher than 81% of companies evaluated by MarketBeat, and ranked 211th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Taysha Gene Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Taysha Gene Therapies has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Taysha Gene Therapies are expected to decrease in the coming year, from ($0.35) to ($0.37) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Taysha Gene Therapies is -7.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Taysha Gene Therapies is -7.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Taysha Gene Therapies has a P/B Ratio of 7.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.70% of the float of Taysha Gene Therapies has been sold short.

Short Interest Ratio / Days to Cover

Taysha Gene Therapies has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Taysha Gene Therapies has recently decreased by 95.67%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Taysha Gene Therapies does not currently pay a dividend.

Dividend Growth

Taysha Gene Therapies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.70% of the float of Taysha Gene Therapies has been sold short.

Short Interest Ratio / Days to Cover

Taysha Gene Therapies has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Taysha Gene Therapies has recently decreased by 95.67%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.70

News Sentiment

Taysha Gene Therapies has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.01 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Taysha Gene Therapies this week, compared to 3 articles on an average week.

Search Interest

Only 7 people have searched for TSHA on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.

MarketBeat Follows

8 people have added Taysha Gene Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Taysha Gene Therapies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,062,500.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 3.78% of the stock of Taysha Gene Therapies is held by insiders.

Percentage Held by Institutions

77.70% of the stock of Taysha Gene Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TSHA Stock Analysis - Frequently Asked Questions

How have TSHA shares performed this year?

Taysha Gene Therapies' stock was trading at $1.73 at the beginning of 2025. Since then, TSHA shares have increased by 52.6% and is now trading at $2.64.

How were Taysha Gene Therapies' earnings last quarter?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) released its quarterly earnings results on Thursday, May, 15th. The company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). The company earned $2.30 million during the quarter, compared to the consensus estimate of $1.48 million. Taysha Gene Therapies had a negative net margin of 1,201.08% and a negative trailing twelve-month return on equity of 104.93%.
Read the conference call transcript.

When did Taysha Gene Therapies IPO?

Taysha Gene Therapies (TSHA) raised $125 million in an IPO on Thursday, September 24th 2020. The company issued 6,600,000 shares at $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies served as the underwriters for the IPO and Chardan was co-manager.

How do I buy shares of Taysha Gene Therapies?

Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Taysha Gene Therapies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Taysha Gene Therapies investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Alphabet (GOOG), Visa (V) and Walt Disney (DIS).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - GENERIC DRG
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TSHA
• CIK: 1806310
• Web: www.tayshagtx.com
• Phone: 214-612-0000
• Fax: N/A
• Employees: 180
• Year Founded: 2020

Price Target and Rating

• Average Price Target for Taysha Gene Therapies: $8.17
• High Price Target: $11.00
• Low Price Target: $6.00
• Potential Upside/Downside: +209.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$89.30 million
• Net Margins: -1,201.08%
• Pretax Margin: -1,201.08%
• Return on Equity: -104.93%
• Return on Assets: -50.09%

Debt

• Debt-to-Equity Ratio: 0.77
• Current Ratio: 5.35
• Quick Ratio: 5.35

Sales & Book Value

• Annual Sales: $7.22 million
• Price / Sales: 78.45
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.35 per share
• Price / Book: 7.54

Miscellaneous

• Outstanding Shares: 214,662,000
• Free Float: 206,548,000
• Market Cap: $566.71 million
• Optionable: Optionable
• Beta: 0.97